Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study

被引:9
|
作者
Du, Rongxu [1 ]
Ming, Jiao [1 ]
Geng, Jianhao [1 ]
Zhu, Xianggao [1 ]
Zhang, Yangzi [1 ]
Li, Shuai [1 ]
Liu, Zhiyan [1 ]
Wang, Hongzhi [1 ]
Wang, Zhilong [2 ]
Tang, Lei [2 ]
Zhang, Xiaotian [3 ]
Wu, Aiwen [4 ]
Bu, Zhaode [4 ]
Yan, Yan [5 ]
Li, Zhongwu [6 ]
Li, Yongheng [1 ]
Li, Ziyu [4 ]
Wang, Weihu [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Med Imaging, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing 100142, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing 100142, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Endoscopy Ctr, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Pathol, Beijing 100142, Peoples R China
关键词
Adenocarcinoma of the oesophagogastric junction; Neoadjuvant chemoradiotherapy; Pathologic response; Inflammation-based and nutrition-related factors; Prediction models; GASTRIC-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; CHEMOTHERAPY; SURGERY; CARCINOMA; ESOPHAGUS; CARDIA;
D O I
10.1186/s13014-022-02016-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Multimodal therapies based on surgical resection have been recommended for the treatment of adenocarcinoma of the oesophagogastric junction (AEG). We aimed to evaluate prognostic factors in AEG patients receiving neoadjuvant chemoradiotherapy and to build predictive models. Methods T3 - T4N + M0 AEG patients with resectable Siewert type II/III tumours were enrolled in this study. All patients underwent neoadjuvant chemoradiation, followed by radical surgery or systemic therapy according to clinical response. Survival analysis was performed using the Kaplan-Meier method; multivariate analysis using the Cox proportional hazards method was also conducted. The Harrell concordance index (C-index) was used to test the prognostic value of models involving prognostic factors, and consistency between actual and predicted survival rates was evaluated by calibration curves. Results From February 2009 to February 2018, 79 patients were treated with neoadjuvant chemoradiotherapy; 60 patients of them underwent radical surgery. The R0 resection rate was 98.3%, and 46.7% of patients achieved a major pathologic response (MPR), namely, a residual tumour issue less than 10%. The 5-year overall survival (OS) rate was 63%, and the 5-year progression-free survival (PFS) rate was 48%. The incidence of grade 3 complications was 21.5%, and no grade 4 complications were reported. According to the results of univariate and multivariate analyses, we included the neutrophil-lymphocyte ratio (NLR), prognostic nutrition index (PNI), eosinophilic granulocyte (EOS) and postoperative pathologic stage in nomogram analysis to establish prediction models for OS and PFS; the C-index of each model was 0.814 and 0.722, respectively. Both the C-index and calibration curves generated to validate consistency between the actual and predicted survival indicated that the models were well calibrated and of good predictive value. Conclusions AEG patients achieved favourable downstaging and pathologic response after neoadjuvant chemoradiation, with acceptable adverse effects. Inflammation-based and nutrition-related factors and postoperative pathologic stage had a significant influence on OS and PFS, and the predictive value was verified through prognostic models.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] A prospective multicenter real-world study on neoadjuvant treatment and clinical outcome in TNBC patients
    Kuehnle, E.
    Kaur, P.
    Siggelkow, W.
    Luebbe, K.
    Schrader, I.
    Uleer, C.
    Noeding, S.
    Noeding, K-H
    Noesselt, T.
    Arfsten, M.
    Busch, C.
    Krentel, N.
    Hillemanns, P.
    Doerk, T.
    Park-Simon, T-W
    CANCER RESEARCH, 2019, 79 (04)
  • [22] Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A real-world experience.
    Ruiz-Garcia, Erika
    Cuervo Cmapos, Rogelio
    Carlos Falcon, Juan
    Caderillo-Ruiz, German
    Diaz Romero, Maria del Consuelo
    Herrera, Marytere
    Miyagui-Adame, Sayako Mariana
    Vela, Itzel
    Alvarez, Nora
    Lino-Silva, Leonardo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 62 - 62
  • [23] Real-world comparison of treatment outcomes between advanced esophagogastric junction adenocarcinoma and gastric adenocarcinoma.
    Kadono, Toru
    Hirose, Toshiharu
    Hirano, Hidekazu
    Shoji, Hirokazu
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 267 - 267
  • [24] A real-world study of active vitamin D as a prognostic marker in patients with sarcoma
    Zhang, Lingyun
    Li, Wei
    Wang, Xiao
    Yu, Shan
    Zhuang, Rongyuan
    Zhou, Yuhong
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [25] Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study
    Li, Jiwei
    Wu, Tao
    Cai, Manbo
    Xie, Changjun
    Ding, Sijuan
    Zou, Wen
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Investigating Incidence of Nausea and Vomiting in Patients Receiving Concurrent Chemoradiotherapy: A Real-World Cohort Study
    Wang, L.
    Zang, J.
    Zhang, Y.
    Yin, Y.
    Wang, P.
    Zhang, J.
    Long, X.
    Zhao, L. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E448 - E449
  • [27] Comparison of neoadjuvant chemoradiotherapy versus chemoradiotherapy plus immunotherapy for esophageal squamous cell carcinoma in a real-world multicenter cohort: a propensity score matching study
    Shi, Shuming
    Zhou, Hao
    Li, Li
    Xu, Fuhao
    Liu, Ning
    Zhang, Dexian
    Xu, Xiaohui
    Sun, Yawen
    Yuan, Shuanghu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Efficacy of adjuvant chemoradiotherapy in patients with pancreatic ductal adenocarcinoma after surgery: A real-world study in high-volume pancreatic cancer center
    Wu, Lili
    Guo, Xi
    Xu, Yaolin
    Wang, Dansong
    Wu, Wenchuan
    Kuang, Tiantao
    Xu, Xuefeng
    Liu, Liang
    Wang, Wenquan
    Du, Shisuo
    Zhou, Yuhong
    Lou, Wenhui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands
    van Laarhoven, Hanneke
    Verhoeven, Rob
    Henegouwen, Mark van Berge
    Mohammad, Nadia Haj
    van Hillegersberg, Richard
    Slingerland, Marije
    Muijs, Christina T.
    Wijnhoven, Bas
    Mostert, Bianca
    Beerepoot, Laurens
    Nieuwenhuijzen, Grard
    Derks, Sarah
    Rossum, Peter S. N. van
    ECLINICALMEDICINE, 2025, 80
  • [30] ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
    JV Reynolds
    SR Preston
    B O’Neill
    L Baeksgaard
    SM Griffin
    C Mariette
    S Cuffe
    M Cunningham
    T Crosby
    I Parker
    K Hofland
    G Hanna
    LB Svendsen
    CL Donohoe
    C Muldoon
    D O’Toole
    C Johnson
    N Ravi
    G Jones
    AK Corkhill
    M Illsley
    J Mellor
    K Lee
    M Dib
    V Marchesin
    M Cunnane
    K Scott
    P Lawner
    S Warren
    S O’Reilly
    G O’Dowd
    G Leonard
    B Hennessy
    R Mc Dermott
    BMC Cancer, 17